YBL 001
Alternative Names: AR-001; YBL-001Latest Information Update: 28 Nov 2025
At a glance
- Originator LegoChem Biosciences; Y-Biologics
- Developer Y-Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
- No development reported Small cell lung cancer
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in South Korea (Parenteral)
- 01 Nov 2023 YBL 001 is still in preclinical trials for Small cell lung cancer in South Korea (Y-Biologics pipeline, October 2023)
- 01 Nov 2023 Preclinical trials in Liver cancer in South Korea (Parenteral) (Y-Biologics pipeline, October 2023)